News

Preclinical studies demonstrate the potential of CRS-100 to stimulate a potent immune response against certain cancers in the liver. Cerus hopes to initiate a phase I clinical trial

As part of the application, Genentech has requested a priority review designation from the FDA, which, if granted, would give the FDA six months from the agency’s receipt

The drug is currently approved for the treatment of acute manic episodes associated with bipolar disorder and the treatment of schizophrenia. Bipolar disorder consists of recurring episodes of

The FDA has requested additional information to address concerns over potential adverse events. Valeant says that it plans to meet with the FDA promptly to discuss the rejection

ADL5859 is a selective novel Delta agonist that has shown activity and an attractive safety profile in preclinical evaluation. The compound is under development for the potential relief

Bristol-Myers Squibb previously disclosed that it could take up to five years for the necessary studies to be completed to satisfy the FDA request. The companies have now

As remuneration for the inclusion of Japan into the VEGF trap collaboration, Regeneron will receive an upfront payment of $25 million, milestone payments related to potential approvals in

If approved, Mesavance would be the first available once-daily mesalamine treatment for active, mild-to-moderate ulcerative colitis. “The timely filing of our Mesavance NDA represents the fourth new product

The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets. Avalon seeks to discover and develop novel therapeutics through the